中國agreementsDesignExamination GuidePatent Law
2023年1月4日

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

by
黃幸兒女士
車李曉芸女士

Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO).

Up until this moment, the World Intellectual Property Organization (WIPO) and the CNIPA1 have been silent on whether a Hong Kong design applicant without a habitual residence or business office in mainland China would be eligible to file a Hague international design application with the CNIPA as a RO.

We recently brought this matter forward to the CNIPA. The CNIPA confirmed that Hong Kong applicants without a habitual residence or business office in mainland China are not eligible to file such type of application with the CNIPA.

A Hague application currently does not cover Hong Kong nor Macao

Although China is included in the current list of the contracting parties of the Hague Agreement, Hong Kong SAR and Macao SAR – both separate jurisdictions having distinct Basic Laws from the People Republic of China – are not included.

This means that Hong Kong and Macao design applicants must file independent design applications in these two regions.

Despite the current situation, things may change in the future. China’s “instrument of accession” (legal document indicating China’s agreement to join the Hague Agreement) provides room for change, stating that the current situation stands “until otherwise notified by the Government of the People’s Republic of China”2. This means that China has already included provisions allowing it to provide notification of changes regarding Hong Kong and Macao in the future.

Stay tuned for more upcoming articles about the other changes in the proposed Patent Examination Guidelines.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. https://www.wipo.int/hague/en/
    https://www.wipo.int/hague/memberprofiles/selectmember#/
    https://www.wipo.int/hague/en/news/2022/news_0005.html
    https://www.wipo.int/treaties/en/notifications/hague/treaty_hague_146.html
    https://wipolex.wipo.int/en/treaties/ShowResults?search_what=C&treaty_id=9
    https://www.cnipa.gov.cn/col/col2893/index.html
    https://www.cnipa.gov.cn/art/2022/10/31/art_75_180016.html
    https://www.cnipa.gov.cn/module/download/downfile.jsp?classid=0&showname=附件1:《专利审查指南修改草案(再次征求意见稿)》修改对照表.pdf&filename=dab071af523943b49eaf1114a84b6234.pdf ↩︎
  2. https://www.wipo.int/hague/en/news/2022/news_0005.html ↩︎

其他文章

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
China Patent 2020 to 2021

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

2020年4月23日
China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

2021年4月30日
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment

2020年7月10日
Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]

我們過去活動

Top crossarrow-right